Exiqon A/S (NASDAQ OMX: EXQ.CO), a leading supplier of high-value gene
expression analysis products, and Health Research, Inc., Roswell Park Cancer
Institute Division, where groundbreaking research by Roswell Park scientists
has led to greater understanding of the nature of cancer and to major advances
in cancer diagnostics and treatments that are now in use worldwide, today
announced that they have signed a Center of Excellence agreement allowing
Roswell Park to provide real-time PCR services based on Exiqon's miRCURY LNA™
Universal RT microRNA PCR product line. The agreement is part of Exiqon's
growing certified service provider program.

LNA™-based microRNA real-time PCR profiling holds great promise as a
non-invasive way to discover important new biomarkers for a wide range of
diseases and biological processes. The extreme sensitivity obtained by
inclusion of LNA™ in the PCR primers allows for the profiling of non-invasive
samples like serum and plasma where the quantity of RNA is extremely low.

This microRNA real-time PCR system combines a Universal RT reaction with
LNA™-enhanced PCR primers, which results in unmatched sensitivity and
specificity for all sample types.

“Roswell Park Cancer Institute has a rich history as a leading cancer center,
and is known for its expertise in the areas of genetics and genomics,” says
Norma J. Nowak, PhD, Director of the Genomics Shared Resource, “miRNAs have
gained prominence in the areas of early detection as well as the potential to
serve as prognostic markers. The Exiqon LNA qPCR platform adds great value to
the current portfolio of assays that we offer our scientific community. We are
excited to be an Exiqon Center of Excellence.”

“We are enthusiastic about Roswell Park Cancer Institute Shared Genomics
Resources personnel and facilities becoming a Center of Excellence,” said
Henrik M Pfundheller, PhD, SVP, Sales & Marketing, and added: “It is exciting
for us to have our miRCURY LNA™ Universal RT microRNA PCR systems as part of
their long history of innovation. We encourage microRNA scientists in their
area to utilize this interesting coupling of our respective proficiencies.”

Additional information:
Lars Kongsbak, President and CEO, Exiqon A/S,
tel. +45 4566 0888 (cell: +45 4090 2101)
Henrik M. Pfundheller, Senior Vice President Sales & Marketing, Exiqon A/S,
tel. +45 4565 0420 (cell: +45 4090 2106)

See the full press release in the attached PDF or at
www.exiqon.com/investor/portal.

PressRelease_October2011_CoE_Rosswell Park.pdf